Evidence map›Paper›PMID 38893528›Full record

ArticleMolecules (Basel, Switzerland)2024

Discovery of Ureido-Substituted 4-Phenylthiazole Derivatives as IGF1R Inhibitors with Potent Antiproliferative Properties.

Yuan Tian, Ni An, Wenru Li, Shixin Tang, Jiqi Li, He Wang, Rongjian Su, Dong Cai

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuan TianCollege of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Ni AnThe Key Laboratory of Molecular and Cellular Biology and Drug Development in Universities of Liaoning Province, Jinzhou Medical University, Jinzhou 121001, China.
Wenru LiCollege of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Shixin TangCollege of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Jiqi LiCollege of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
He WangCollege of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Rongjian SuThe Key Laboratory of Molecular and Cellular Biology and Drug Development in Universities of Liaoning Province, Jinzhou Medical University, Jinzhou 121001, China.
Dong CaiCollege of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.

Funding

he Liaoning Province Science and Technology Plan Joint Program Project 2023-MSLH-043the Basic Scientific Research Project (Key Project) of Liaoning Provincial Department of Education JYTZD201912the Chinese College Student Innovation and Entrepreneurship Training Program 202310160003Xthe Liaoning Provincial Department of Education General Research Project in the field of Natural Science jytms20231744
6 · The paper itself

Abstract

The existing kinase inhibitors for hepatocellular carcinoma (HCC) have conferred survival benefits but are hampered by adverse effects and drug resistance, necessitating the development of novel agents targeting distinct pathways. To discover potent new anti-HCC compounds, we leveraged scaffold hopping from Sorafenib and introduced morpholine/piperidine moieties to develop ureido-substituted 4-phenylthiazole analogs with optimized physicochemical properties and binding interactions. Notably, compound

Indexed as

Antineoplastic AgentsApoptosisCell ProliferationProtein Kinase InhibitorsReceptor, IGF Type 1ThiazolesCarcinoma, HepatocellularCell Line, TumorCell MovementHep G2 CellsHumansLiver NeoplasmsModels, MolecularMolecular Docking SimulationMolecular StructureReceptors, SomatomedinAntineoplastic AgentsIGF1R protein, humanProtein Kinase InhibitorsReceptor, IGF Type 1Receptors, SomatomedinSorafenibThiazolesanticancerHCCinhibitorsmolecular modelingureido of 4-phenylthiazole derivatives

Identifiers

PMID38893528
PMCPMC11173463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.